The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Saroglitazar for the treatment of NASH: the PPAR story goes on!
Hepatology. 2021 Jun 23. doi: 10.1002/hep.32024. Online ahead of print.
Sven Ma Francque1234
Author information
1Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
2Laboratory of Experimental Medicine and Paediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
3InflaMed Centre of Excellence, University of Antwerp, Antwerp, Belgium.
4Translational Sciences in Inflammation and Immunology, University of Antwerp, Antwerp, Belgium.
Abstract
Despite intensive research, no drug has to date been approved for the management of NAFLD, and many clinical trials have failed, including some recent large phase 3 trials. This has in part to do with the complex disease pathophysiology, which is only partially unravelled(1). Furthermore, the disease is embedded in a set of metabolic drivers, creating an environment of metabolic and inflammatory stress.